oxandrolone has been researched along with Body Weight in 34 studies
Oxandrolone: A synthetic hormone with anabolic and androgenic properties.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In a randomized trial, we compared the effects of 2 months of treatment with either megestrol acetate (800 mg every day) or oxandrolone (10 mg twice per day) on body weight and composition in patients with weight loss of > or =5 kg who were receiving HAART." | 9.11 | Comparing megestrol acetate therapy with oxandrolone therapy for HIV-related weight loss: similar results in 2 months. ( Albrecht, M; Chang, H; Forfia, J; Gerrior, J; Miller, L; Mwamburi, DM; Saboori, S; Scully, E; Wanke, CA; Wilson, IB, 2004) |
| "Oxandrolone is an effective adjunct to facilitate weight restoration in patients with COPD-associated weight loss." | 9.10 | Reversal of COPD-associated weight loss using the anabolic agent oxandrolone. ( DeGuzman, B; Kramer, T; Yeh, SS, 2002) |
| " Mortality, infection, and hepatic function: Oxandrolone therapy did not affect mortality (relative risk (RR)=0." | 8.93 | The efficacy and safety of oxandrolone treatment for patients with severe burns: A systematic review and meta-analysis. ( Guo, Q; Guo, Y; Li, H; Roy, M; Yang, Z, 2016) |
| "Severe burns are associated with a significant loss of muscle and strength." | 6.73 | The effects of oxandrolone and exercise on muscle mass and function in children with severe burns. ( Herndon, DN; Przkora, R; Suman, OE, 2007) |
| " Conventional GH doses are effective in increasing growth velocity in UTS, especially, when combined with Ox." | 6.68 | Treatment of patients with Ullrich-Turner syndrome with conventional doses of growth hormone and the combination with testosterone or oxandrolone: effect on growth, IGF-I and IGFBP-3 concentrations. ( Blümel, P; Frisch, H; Haeusler, G; Plöchl, E; Schmitt, K; Waldhör, T; Zachmann, M, 1995) |
| " In a randomized trial, we compared the effects of 2 months of treatment with either megestrol acetate (800 mg every day) or oxandrolone (10 mg twice per day) on body weight and composition in patients with weight loss of > or =5 kg who were receiving HAART." | 5.11 | Comparing megestrol acetate therapy with oxandrolone therapy for HIV-related weight loss: similar results in 2 months. ( Albrecht, M; Chang, H; Forfia, J; Gerrior, J; Miller, L; Mwamburi, DM; Saboori, S; Scully, E; Wanke, CA; Wilson, IB, 2004) |
| "Oxandrolone is an effective adjunct to facilitate weight restoration in patients with COPD-associated weight loss." | 5.10 | Reversal of COPD-associated weight loss using the anabolic agent oxandrolone. ( DeGuzman, B; Kramer, T; Yeh, SS, 2002) |
| "In healthy subjects with tetraplegia, the use of oxandrolone was associated with significant improvements in weight and pulmonary function, and a subjective reduction in breathlessness." | 5.09 | Treatment with an anabolic agent is associated with improvement in respiratory function in persons with tetraplegia: a pilot study. ( Bauman, WA; Grimm, DR; Pizzolato, PM; Spungen, AM; Strakhan, M, 1999) |
| " Mortality, infection, and hepatic function: Oxandrolone therapy did not affect mortality (relative risk (RR)=0." | 4.93 | The efficacy and safety of oxandrolone treatment for patients with severe burns: A systematic review and meta-analysis. ( Guo, Q; Guo, Y; Li, H; Roy, M; Yang, Z, 2016) |
| "Severe burns are associated with a significant loss of muscle and strength." | 2.73 | The effects of oxandrolone and exercise on muscle mass and function in children with severe burns. ( Herndon, DN; Przkora, R; Suman, OE, 2007) |
| "Treatment with oxandrolone for 3 months in HIV-infected children was well-tolerated, safe, and associated with markers of anabolism." | 2.69 | Evaluation of the effects of oxandrolone on malnourished HIV-positive pediatric patients. ( Barton, N; Church, JA; Fox-Wheeler, S; Gilsanz, V; Haight, M; Heller, L; Kaufman, F; Loro, ML; Salata, CM; Umman, GC, 1999) |
| " Conventional GH doses are effective in increasing growth velocity in UTS, especially, when combined with Ox." | 2.68 | Treatment of patients with Ullrich-Turner syndrome with conventional doses of growth hormone and the combination with testosterone or oxandrolone: effect on growth, IGF-I and IGFBP-3 concentrations. ( Blümel, P; Frisch, H; Haeusler, G; Plöchl, E; Schmitt, K; Waldhör, T; Zachmann, M, 1995) |
| " Multicenter, prospective, randomized studies are needed to better define the optimal oxandrolone dosage and to confirm the efficacy and safety of this drug in adult patients with severe thermal injury." | 2.45 | Oxandrolone treatment in adults with severe thermal injury. ( Btaiche, IF; Miller, JT, 2009) |
| "Nephrotic syndrome was induced by a single i." | 1.25 | Efficacy and interactions of oxandrolone, halo-fenate and clofibrate in a factorial study on experimental acute nephrotic hyperlipidemia. ( Edwards, KD; Schapel, GJ, 1975) |
| " Half of the compounds decreased uterine weight at lower doses but increased it at higher doses within the dosage range (1-4000 micrograms/day)." | 1.25 | Anti-ovulatory effects of some androgenic-myotrophic steroids in the pubertal rat. ( Boris, A; Nelson, EW; Trmal, T, 1972) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 17 (50.00) | 18.7374 |
| 1990's | 6 (17.65) | 18.2507 |
| 2000's | 9 (26.47) | 29.6817 |
| 2010's | 2 (5.88) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dobbe, L | 1 |
| Clapp, C | 1 |
| Larumbe-Zabala, E | 1 |
| Griswold, J | 1 |
| Li, H | 1 |
| Guo, Y | 1 |
| Yang, Z | 1 |
| Roy, M | 1 |
| Guo, Q | 1 |
| Miller, JT | 1 |
| Btaiche, IF | 1 |
| Yeh, SS | 1 |
| DeGuzman, B | 1 |
| Kramer, T | 1 |
| RAY, CG | 1 |
| KIRSCHVINK, JF | 1 |
| WAXMAN, SH | 1 |
| KELLEY, VC | 1 |
| METCALF, W | 1 |
| BLUMBERG, H | 1 |
| ROACH, J | 1 |
| DANOWSKI, TS | 1 |
| LEE, FA | 1 |
| COHN, RE | 1 |
| D AMBROSIA, RD | 1 |
| LIMAYE, NR | 1 |
| Schroeder, ET | 1 |
| Zheng, L | 1 |
| Yarasheski, KE | 1 |
| Qian, D | 1 |
| Stewart, Y | 1 |
| Flores, C | 1 |
| Martinez, C | 1 |
| Terk, M | 1 |
| Sattler, FR | 1 |
| Mwamburi, DM | 1 |
| Gerrior, J | 1 |
| Wilson, IB | 1 |
| Chang, H | 1 |
| Scully, E | 1 |
| Saboori, S | 1 |
| Miller, L | 1 |
| Forfia, J | 1 |
| Albrecht, M | 1 |
| Wanke, CA | 1 |
| Parvin, M | 1 |
| Roche, E | 1 |
| Costigan, C | 1 |
| Hoey, HM | 1 |
| Przkora, R | 1 |
| Herndon, DN | 1 |
| Suman, OE | 1 |
| Zangeneh, F | 1 |
| Steiner, MM | 1 |
| Gherondache, CN | 1 |
| Dowling, WJ | 1 |
| Pincus, G | 1 |
| Krause, BR | 1 |
| Hartman, AD | 1 |
| Haeusler, G | 1 |
| Frisch, H | 1 |
| Schmitt, K | 1 |
| Blümel, P | 1 |
| Plöchl, E | 1 |
| Zachmann, M | 1 |
| Waldhör, T | 1 |
| Demling, R | 1 |
| De Santi, L | 1 |
| Spungen, AM | 1 |
| Grimm, DR | 1 |
| Strakhan, M | 1 |
| Pizzolato, PM | 1 |
| Bauman, WA | 1 |
| Fox-Wheeler, S | 1 |
| Heller, L | 1 |
| Salata, CM | 1 |
| Kaufman, F | 1 |
| Loro, ML | 1 |
| Gilsanz, V | 1 |
| Haight, M | 1 |
| Umman, GC | 1 |
| Barton, N | 1 |
| Church, JA | 1 |
| Earthman, CP | 1 |
| Matthie, JR | 1 |
| Reid, PM | 1 |
| Harper, IT | 1 |
| Ravussin, E | 1 |
| Howell, WH | 1 |
| Langer, CJ | 1 |
| Hoffman, JP | 1 |
| Ottery, FD | 1 |
| Rosenfeld, J | 1 |
| King, RM | 1 |
| Smith, JE | 1 |
| Schapel, GJ | 1 |
| Edwards, KD | 1 |
| Stahnke, N | 1 |
| Stubbe, P | 1 |
| Keller, E | 1 |
| Forbes, GB | 1 |
| Bettmann, HK | 1 |
| Goldman, HS | 1 |
| Abramowicz, M | 1 |
| Sobel, EH | 1 |
| Selye, H | 2 |
| Boris, A | 1 |
| Trmal, T | 1 |
| Nelson, EW | 1 |
| Rosenbloom, AL | 1 |
| Frias, JL | 1 |
| Bray, GA | 1 |
| Raben, MS | 1 |
| Londono, J | 1 |
| Gallagher, TF | 1 |
| Jelinek, J | 1 |
| Krajny, M | 1 |
| Sansoy, OM | 1 |
| Roy, AN | 1 |
| Shields, LM | 1 |
| Harada, H | 1 |
| Osawa, K | 1 |
| Otsuka, S | 1 |
| Wada, S | 1 |
| Kiuchi, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Testosterone Gel to Restore Normal Serum Values of Testosterone During the Acute Phase of Critical Illness in Adult ICU Patients[NCT03678233] | Phase 2 | 30 participants (Anticipated) | Interventional | 2019-06-27 | Recruiting | ||
| Efficacy and Safety of Fispemifene in the Treatment of Hypogonadal Men With Chronic Obstructive Pulmonary Disease That Are on Oral Glucocorticoid Therapy: A 4-Week, Randomized, Double-Blind, Placebo-Controlled Study[NCT01061970] | Phase 2 | 15 participants (Anticipated) | Interventional | 2007-01-31 | Completed | ||
| Randomized, Controlled, Multicenter Study of the Effect of In-Patient Exercise Training on Length of Hospitalization, Mental Health, and Physical Performance in Burned Patients[NCT02739464] | 77 participants (Actual) | Interventional | 2014-09-15 | Completed | |||
| Xbox Kinect™ to Promote Physical Fitness and Lean Mass in Severely Burned Children: A Randomized Controlled Trial[NCT04350034] | 40 participants (Actual) | Interventional | 2016-06-15 | Completed | |||
| Effect of Mirtazapine Versus Placebo on Appetite, Nutritional Status and Quality of Life in Non-small Cell Lung cáncer Patients With Anorexia; Randomized Double-blind Clinical Trial.[NCT04748523] | 86 participants (Actual) | Interventional | 2018-08-29 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for oxandrolone and Body Weight
| Article | Year |
|---|---|
The efficacy and safety of oxandrolone treatment for patients with severe burns: A systematic review and meta-analysis.
Topics: Anabolic Agents; Body Composition; Body Weight; Burns; Chemical and Drug Induced Liver Injury; Human | 2016 |
Oxandrolone treatment in adults with severe thermal injury.
Topics: Adult; Anabolic Agents; Body Weight; Burns; Clinical Trials as Topic; Humans; Nutritional Support; O | 2009 |
Clinical significance of weight loss in cancer patients: rationale for the use of anabolic agents in the treatment of cancer-related cachexia.
Topics: Anabolic Agents; Appetite Stimulants; Body Weight; Cachexia; HIV Wasting Syndrome; Humans; Neoplasms | 2001 |
Protection by catatoxic steroids against cyclophosphamide-induced organ lesions.
Topics: Adrenal Glands; Animals; Body Weight; Bone Marrow; Cyclophosphamide; Desoxycorticosterone; Enzyme In | 1970 |
12 trials available for oxandrolone and Body Weight
| Article | Year |
|---|---|
Reversal of COPD-associated weight loss using the anabolic agent oxandrolone.
Topics: Aged; Anabolic Agents; Body Composition; Body Weight; Exercise Tolerance; Female; Humans; Karnofsky | 2002 |
Treatment with oxandrolone and the durability of effects in older men.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Body Composition; Body Mass Index; Body Weight; Doubl | 2004 |
Comparing megestrol acetate therapy with oxandrolone therapy for HIV-related weight loss: similar results in 2 months.
Topics: Adult; Androgens; Antiretroviral Therapy, Highly Active; Body Weight; Female; HIV Infections; Humans | 2004 |
The effects of oxandrolone and exercise on muscle mass and function in children with severe burns.
Topics: Adolescent; Anabolic Agents; Body Mass Index; Body Weight; Burns; Child; Exercise Test; Exercise The | 2007 |
The effects of oxandrolone and exercise on muscle mass and function in children with severe burns.
Topics: Adolescent; Anabolic Agents; Body Mass Index; Body Weight; Burns; Child; Exercise Test; Exercise The | 2007 |
The effects of oxandrolone and exercise on muscle mass and function in children with severe burns.
Topics: Adolescent; Anabolic Agents; Body Mass Index; Body Weight; Burns; Child; Exercise Test; Exercise The | 2007 |
The effects of oxandrolone and exercise on muscle mass and function in children with severe burns.
Topics: Adolescent; Anabolic Agents; Body Mass Index; Body Weight; Burns; Child; Exercise Test; Exercise The | 2007 |
Metabolic changes induced in elderly patients with an anabolic steroid (oxandrolone).
Topics: Acid Phosphatase; Aged; Aspartate Aminotransferases; Blood Urea Nitrogen; Body Weight; Calcium; Chol | 1967 |
Treatment of patients with Ullrich-Turner syndrome with conventional doses of growth hormone and the combination with testosterone or oxandrolone: effect on growth, IGF-I and IGFBP-3 concentrations.
Topics: Age Determination by Skeleton; Body Height; Body Weight; Carrier Proteins; Child; Drug Therapy, Comb | 1995 |
Treatment with an anabolic agent is associated with improvement in respiratory function in persons with tetraplegia: a pilot study.
Topics: Anabolic Agents; Body Weight; Dyspnea; Humans; Male; Oxandrolone; Pilot Projects; Quadriplegia | 1999 |
Evaluation of the effects of oxandrolone on malnourished HIV-positive pediatric patients.
Topics: Adolescent; Anabolic Agents; Body Weight; CD4 Lymphocyte Count; Chi-Square Distribution; Child; Chil | 1999 |
Anabolic steroid now available.
Topics: Anabolic Agents; Body Weight; Double-Blind Method; HIV Wasting Syndrome; Humans; Oxandrolone | 1996 |
Oxandrolone in ALS: preliminary analysis.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Anabolic Agents; Body Weight; Female; Humans; Isometric | 2000 |
Recombinant human growth hormone and oxandrolone in treatment of short stature in girls with Turner syndrome.
Topics: Aging; Body Height; Body Weight; Bone Development; Child; Female; Growth Disorders; Growth Hormone; | 1992 |
Effects of triiodothyronine, growth hormone and anabolic steroids on nitrogen excretion and oxygen consumption of obese patients.
Topics: Adult; Body Weight; Clinical Trials as Topic; Female; Growth Hormone; Humans; Methandrostenolone; Mi | 1971 |
18 other studies available for oxandrolone and Body Weight
| Article | Year |
|---|---|
Assessment of the impact of oxandrolone on outcomes in burn injured patients.
Topics: Adult; Anabolic Agents; Body Weight; Burns; Burns, Inhalation; Female; Humans; Length of Stay; Longi | 2019 |
STUDIES OF ANABOLIC STEROIDS. II. THE EFFECT OF OXANDROLONE ON HEIGHT AND SKELETAL MATURATION IN MONGOLOID CHILDREN (A PRELIMINARY REPORT).
Topics: Adolescent; Aging; Anabolic Agents; Body Height; Body Weight; Child; Down Syndrome; Epiphyses; Growt | 1963 |
A QUANTITATIVE EXPRESSION FOR NITROGEN RETENTION WITH ANABOLIC STEROIDS. IV. OXANDROLONE.
Topics: Body Weight; Body Weights and Measures; Nitrogen; Oxandrolone; Pharmacology; Proteins; Statistics as | 1965 |
OXANDROLONE THERAPY OF GROWTH RETARDATION.
Topics: Adolescent; Adrenal Insufficiency; Age Determination by Skeleton; Anemia; Anemia, Sickle Cell; Blood | 1965 |
Treatment outcome in Turner syndrome.
Topics: Adolescent; Body Height; Body Weight; Child; Dose-Response Relationship, Drug; Drug Administration S | 2004 |
Oxandrolone therapy in growth retardation of children.
Topics: Adolescent; Body Height; Body Weight; Bone Development; Child; Child, Preschool; Female; Growth; Hum | 1967 |
Accumulation of adipocyte cholesterol during hypolipidemic drug treatment in cholesterol-fed rats.
Topics: Adipose Tissue; Animals; Body Weight; Cholesterol; Cholesterol, Dietary; Cholestyramine Resin; Clofi | 1982 |
Closure of the "non-healing wound" corresponds with correction of weight loss using the anabolic agent oxandrolone.
Topics: Adult; Aged; Aged, 80 and over; Anabolic Agents; Body Weight; Combined Modality Therapy; Debridement | 1998 |
A comparison of bioimpedance methods for detection of body cell mass change in HIV infection.
Topics: Adult; Anabolic Agents; Body Water; Body Weight; Electric Impedance; Evaluation Studies as Topic; Ex | 2000 |
Efficacy and interactions of oxandrolone, halo-fenate and clofibrate in a factorial study on experimental acute nephrotic hyperlipidemia.
Topics: Animals; Body Weight; Butyrates; Cholesterol; Clofibrate; Dose-Response Relationship, Drug; Drug Eva | 1975 |
The effect of anabolic steroids on lean body mass: the dose response curve.
Topics: Adult; Anabolic Agents; Body Weight; Dose-Response Relationship, Drug; Female; Humans; Male; Nitroge | 1985 |
Oxandrolone treatment of short stature: effect on predicted mature height.
Topics: Adolescent; Age Determination by Skeleton; Body Height; Body Weight; Bone Development; Child; Child, | 1971 |
Anti-ovulatory effects of some androgenic-myotrophic steroids in the pubertal rat.
Topics: Androgens; Androstenes; Animals; Body Weight; Depression, Chemical; Dihydrotestosterone; Ethylestren | 1972 |
Oxandrolone for growth promotion in Turner syndrome.
Topics: Adolescent; Body Height; Body Weight; Bone and Bones; Child; Female; Growth; Humans; Osteogenesis; O | 1973 |
American Academy of Pediatrics. Committee on Drugs. Counseling and synthetic steroids in short stature without organic disease.
Topics: Adaptation, Psychological; Adolescent; Body Height; Body Weight; Child; Counseling; Female; Fluoxyme | 1974 |
Prevention of digitoxin poisoning by various steroids.
Topics: Anabolic Agents; Androstanes; Animals; Body Weight; Desoxycorticosterone; Digitoxin; Diuretics; Estr | 1969 |
Anabolic action and side effects of oxandrolone in 34 mental patients.
Topics: Adult; Age Factors; Aged; Arthritis; Aspartate Aminotransferases; Blood Chemical Analysis; Body Weig | 1971 |
[Clinical experience with 17-beta-hydroxy-17-alpha-methyl-2-oxa-5-alpha-androstan-3-one (oxandrolone)].
Topics: Adolescent; Adult; Anorexia Nervosa; Body Weight; Cerebral Hemorrhage; Female; Humans; Intracranial | 1969 |